Sarah M Clark1, Ana Pocivavsek1, James D Nicholson1, Francesca M Notarangelo1, Patricia Langenberg1, Robert P McMahon1, Joel E Kleinman1, Thomas M Hyde1, John Stiller1, Teodor T Postolache1, Robert Schwarcz1, Leonardo H Tonelli1. 1. From the Laboratory of Behavioral Neuroimmunology, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD (Clark, Nicholson, Tonelli); the Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD (Pocivavsek, Notarangelo, McMahon, Schwarcz); the Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD (Langenberg); the Section on Neuropathology, Clinical Brain Disorders Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland (Kleinman, Hyde); the Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD (Kleinman, Hyde); and the Mood and Anxiety Program, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD (Stiller, Postolache).
Abstract
BACKGROUND: Neuroinflammatory processes are increasingly believed to participate in the pathophysiology of a number of major psychiatric diseases, including depression. Immune activation stimulates the conversion of the amino acid tryptophan to kynurenine, leading to the formation of neuroactive metabolites, such as quinolinic acid and kynurenic acid. These compounds affect glutamatergic neurotransmission, which plays a prominent role in depressive pathology. Increased tryptophan degradation along the kynurenine pathway (KP) has been proposed to contribute to disease etiology. METHODS: We used postmortem brain tissue from the ventrolateral prefrontal cortex (VLPFC) to assess tissue levels of tryptophan and KP metabolites, the expression of several KP enzymes and a series of cytokines as well as tissue pathology, including microglial activation. Tissue samples came from nonpsychiatric controls (n = 36) and individuals with depressive disorder not otherwise specified (DD-NOS, n = 45) who died of natural causes, homicide, accident, or suicide. RESULTS: We found a reduction in the enzymatic conversion of tryptophan to kynurenine, determined using the kynurenine:tryptophan ratio, and reduced messenger RNA expression of the enzymes indoleamine-2,3-dioxygenase 1 and 2 and tryptophan-2,3-dioxygenase in depressed individuals irrespective of the cause of death. These findings correlated with reductions in the expression of several cytokines, including interferon-γ and tumour necrosis factor-α. Notably, quinolinic acid levels were also lower in depressed individuals than controls. LIMITATIONS: Information on the use of antidepressants and other psychotropic medications was insufficient for statistical comparisons. CONCLUSION: Contrary to expectations, the present results indicate that depression, in the absence of medical illness or an overt inflammatory process, is associated with compromised, rather than increased, KP metabolism in the VLPFC.
BACKGROUND: Neuroinflammatory processes are increasingly believed to participate in the pathophysiology of a number of major psychiatric diseases, including depression. Immune activation stimulates the conversion of the amino acid tryptophan to kynurenine, leading to the formation of neuroactive metabolites, such as quinolinic acid and kynurenic acid. These compounds affect glutamatergic neurotransmission, which plays a prominent role in depressive pathology. Increased tryptophan degradation along the kynurenine pathway (KP) has been proposed to contribute to disease etiology. METHODS: We used postmortem brain tissue from the ventrolateral prefrontal cortex (VLPFC) to assess tissue levels of tryptophan and KP metabolites, the expression of several KP enzymes and a series of cytokines as well as tissue pathology, including microglial activation. Tissue samples came from nonpsychiatric controls (n = 36) and individuals with depressive disorder not otherwise specified (DD-NOS, n = 45) who died of natural causes, homicide, accident, or suicide. RESULTS: We found a reduction in the enzymatic conversion of tryptophan to kynurenine, determined using the kynurenine:tryptophan ratio, and reduced messenger RNA expression of the enzymes indoleamine-2,3-dioxygenase 1 and 2 and tryptophan-2,3-dioxygenase in depressed individuals irrespective of the cause of death. These findings correlated with reductions in the expression of several cytokines, including interferon-γ and tumour necrosis factor-α. Notably, quinolinic acid levels were also lower in depressed individuals than controls. LIMITATIONS: Information on the use of antidepressants and other psychotropic medications was insufficient for statistical comparisons. CONCLUSION: Contrary to expectations, the present results indicate that depression, in the absence of medical illness or an overt inflammatory process, is associated with compromised, rather than increased, KP metabolism in the VLPFC.
Authors: Paul J Kennedy; Andrew P Allen; Ann O'Neill; Eamonn M M Quigley; John F Cryan; Timothy G Dinan; Gerard Clarke Journal: Psychopharmacology (Berl) Date: 2014-10-23 Impact factor: 4.530
Authors: Martina M Hughes; Angela Carballedo; Declan M McLoughlin; Francesco Amico; Andrew Harkin; Thomas Frodl; Thomas J Connor Journal: Brain Behav Immun Date: 2012-06-06 Impact factor: 7.217
Authors: Ghanshyam N Pandey; Hooriyah S Rizavi; Xinguo Ren; Jawed Fareed; Debra A Hoppensteadt; Rosalinda C Roberts; Robert R Conley; Yogesh Dwivedi Journal: J Psychiatr Res Date: 2011-09-08 Impact factor: 4.791
Authors: Carlos Zarate; Ronald S Duman; Guosong Liu; Simone Sartori; Jorge Quiroz; Harald Murck Journal: Ann N Y Acad Sci Date: 2013-07 Impact factor: 5.691
Authors: Marko Elovainio; Mikko Hurme; Markus Jokela; Laura Pulkki-Råback; Mika Kivimäki; Mirka Hintsanen; Taina Hintsa; Terho Lehtimäki; Jorma Viikari; Olli T Raitakari; Liisa Keltikangas-Järvinen Journal: Psychosom Med Date: 2012-08-28 Impact factor: 4.312
Authors: T Kreisel; M G Frank; T Licht; R Reshef; O Ben-Menachem-Zidon; M V Baratta; S F Maier; R Yirmiya Journal: Mol Psychiatry Date: 2013-12-17 Impact factor: 15.992
Authors: Gouri J Mahajan; Eric J Vallender; Michael R Garrett; Lavanya Challagundla; James C Overholser; George Jurjus; Lesa Dieter; Maryam Syed; Damian G Romero; Hamed Benghuzzi; Craig A Stockmeier Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-11-22 Impact factor: 5.067
Authors: Eric Achtyes; Sarah A Keaton; LeAnn Smart; Amanda R Burmeister; Patrick L Heilman; Stanislaw Krzyzanowski; Madhavi Nagalla; Gilles J Guillemin; Martha L Escobar Galvis; Chai K Lim; Maria Muzik; Teodor T Postolache; Richard Leach; Lena Brundin Journal: Brain Behav Immun Date: 2019-11-05 Impact factor: 7.217
Authors: E E M Knowles; Joanne E Curran; Harald H H Göring; Samuel R Mathias; Josephine Mollon; Amanda Rodrigue; Rene L Olvera; Ana Leandro; Ravi Duggirala; Laura Almasy; John Blangero; David C Glahn Journal: Brain Behav Immun Date: 2019-04-03 Impact factor: 7.217